Researchers at the Université de Genève have developed a programmable DNA-based drug delivery system that targets cancer cells with remarkable precision while sparing healthy tissues. This innovative approach utilizes synthetic DNA strands that activate only upon detecting specific combinations of tumor markers, effectively minimizing collateral damage during treatment. The system’s ability to deliver multiple drugs simultaneously also addresses the challenge of drug resistance, marking a significant advancement in cancer therapeutics.

The significance of this development lies in its potential to enhance the efficacy of targeted therapies. Traditional methods, such as antibody-drug conjugates (ADCs), face limitations due to their size and capacity for drug delivery. In contrast, the smaller DNA strands in this new system can navigate tumor microenvironments more effectively. By employing a “Two-Key” system, the drug components remain inactive until both required cancer markers are identified, ensuring a high degree of selectivity. Laboratory results have demonstrated the system’s ability to deliver potent drugs directly to cancer cells without affecting adjacent healthy cells, showcasing its therapeutic promise.

This research shifts the paradigm in drug development by introducing a self-operating drug system that mimics computational logic at the molecular level. The implications for personalized medicine are profound, as these “smart” drugs could adapt to individual patient biology, improving treatment outcomes while reducing side effects. By enhancing the precision and control of cancer therapies, this technology opens new avenues for the development of programmable medicines, potentially transforming how diseases are treated in the future.

Source: sciencedaily.com